Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Among authors: reardon da. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma.
Mahalingam P, Smith S, Lopez J, Sharma RK, Millard T, Thway K, Fisher C, Reardon DA, Jones R, Nicholson AG, Cunningham D, Welsh L, Sharma B. Mahalingam P, et al. Among authors: reardon da. Rare Tumors. 2023 Jan 19;15:20363613231152333. doi: 10.1177/20363613231152333. eCollection 2023. Rare Tumors. 2023. PMID: 36698626 Free PMC article.
An expanded role for surgery in grade 3 1p/19q co-deleted oligodendroglioma.
Gupta S, Nawabi NL, Emani S, Medeiros L, Bernstock JD, Duvall J, Ng P, Smith TR, Wen PY, Reardon DA, Arnaout O. Gupta S, et al. Among authors: reardon da. Neurooncol Adv. 2023 Apr 21;5(1):vdad046. doi: 10.1093/noajnl/vdad046. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37215951 Free PMC article.
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. Brastianos PK, et al. Among authors: reardon da. N Engl J Med. 2023 Jul 13;389(2):118-126. doi: 10.1056/NEJMoa2213329. N Engl J Med. 2023. PMID: 37437144 Free PMC article. Clinical Trial.
Glioma genetic profiles associated with electrophysiologic hyperexcitability.
Tobochnik S, Dorotan MKC, Ghosh HS, Lapinskas E, Vogelzang J, Reardon DA, Ligon KL, Bi WL, Smirnakis SM, Lee JW. Tobochnik S, et al. Among authors: reardon da. Neuro Oncol. 2024 Feb 2;26(2):323-334. doi: 10.1093/neuonc/noad176. Neuro Oncol. 2024. PMID: 37713468 Free PMC article.
Glioma genetic profiles associated with electrophysiologic hyperexcitability.
Tobochnik S, Dorotan MKC, Ghosh HS, Lapinskas E, Vogelzang J, Reardon DA, Ligon KL, Bi WL, Smirnakis SM, Lee JW. Tobochnik S, et al. Among authors: reardon da. medRxiv [Preprint]. 2023 Feb 24:2023.02.22.23285841. doi: 10.1101/2023.02.22.23285841. medRxiv. 2023. Update in: Neuro Oncol. 2024 Feb 2;26(2):323-334. doi: 10.1093/neuonc/noad176 PMID: 36865325 Free PMC article. Updated. Preprint.
Metastatic pituitary tumors: an institutional case series.
Yearley AG, Chalif EJ, Gupta S, Chalif JI, Bernstock JD, Nawabi N, Arnaout O, Smith TR, Reardon DA, Laws ER. Yearley AG, et al. Among authors: reardon da. Pituitary. 2023 Oct;26(5):561-572. doi: 10.1007/s11102-023-01341-4. Epub 2023 Jul 31. Pituitary. 2023. PMID: 37523025
Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma.
Paes T, Buelvas Mebarak J, Magnotto JC, Stamatiades GA, Kuang Y, Paweletz C, Laws ER, Grosek N, Carroll RS, Jeselsohn R, Mohan DR, Lerario AM, Truong MT, Bi WL, Reardon DA, Meredith DM, Kaiser UB, Abreu AP. Paes T, et al. Among authors: reardon da. J Clin Endocrinol Metab. 2024 Sep 6:dgae615. doi: 10.1210/clinem/dgae615. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39238355
393 results